医学
人类免疫缺陷病毒(HIV)
抗逆转录病毒疗法
内科学
人口
梅德林
西达
病毒学
队列
入射(几何)
疾病
队列研究
流行病学
病毒载量
作者
Hanlu Jia,Zhao Yan,Yuan Guan,Liu Jiang,Yunxia Geng,Xiumin Gan,Liu Yufen
出处
期刊:China CDC weekly
[Chinese Center for Disease Control and Prevention]
日期:2026-07-03
卷期号:8 (27): 835-840
标识
DOI:10.46234/ccdcw2026.137
摘要
What is already known about this topic?: Antiretroviral therapy (ART) is the cornerstone of HIV care. In China, efavirenz-based regimens have long been widely used as first-line treatment, while integrase strand transfer inhibitor (INSTI)-based regimens are increasingly available. However, nationwide evidence on virologic outcomes across common first-line regimens remains limited. What is added by this report?: This nationwide cohort study found higher viral suppression with EFV 400 mg-based regimens compared with EFV 600 mg- and LPV/r-based regimens, while INSTI-based regimens showed the highest suppression overall. What are the implications for public health practice?: Findings support expanded use of INSTI-based regimens and consideration of EFV 400 mg-based regimens during ongoing optimization of first-line ART in China.
科研通智能强力驱动
Strongly Powered by AbleSci AI